GlassScriptPhysician profile
Brad L Andersen
NPI 1598831406
$1,594.50
in general payments reported to CMS, 2019-2025
24 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $162 · 2022: $44.62 · 2023: $157 · 2024: $370 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.03 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $177.44 | 2019-2025 | Breztri |
| Lilly USA, LLC | $166.17 | 2019-2025 | Zepbound, Mounjaro, Lyumjev |
| Novo Nordisk INC | $147.97 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $141.01 | 2019-2025 | |
| Amgen INC. | $136.10 | 2019-2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.28 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $85.33 | 2022-2024 | |
| Abbvie INC. | $76.67 | 2023-2024 | Qulipta, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $72.05 | 2019-2025 | Trintellix |
| Aimmune Therapeutics, INC. | $62.66 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.17 | 2019-2024 | Xifaxan, Trulance |
| Allergan, INC. | $51.14 | 2019 | |
| Glaxosmithkline, LLC. | $45.01 | 2019-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $41.29 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $36.96 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $33.21 | 2020-2023 | Tymlos |
| Merck Sharp & Dohme LLC | $27.59 | 2019 | |
| Exact Sciences Corporation | $22.17 | 2024 | Cologuard Collection Kit |
| Celgene Corporation | $18.94 | 2019 | |
| Kaleo, INC. | $17.65 | 2020 | |
| Hologic Sales and Service, LLC | $16.97 | 2023 | Thinprep 2000 Processor, Aptima |
| Sanofi-Aventis U.S. LLC | $16.86 | 2019 | |
| Linus Health, INC. | $11.96 | 2024 | Core Cognitive Evaluation |
| Phathom Pharmaceuticals, INC. | $11.90 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.